Table 5 Prognostic factors for DFS and OS by univariate analysis
From: The prognostic value of combined TGF-β1 and ELF in hepatocellular carcinoma
| Variables | n | DFS | P | OS | P | ||||
|---|---|---|---|---|---|---|---|---|---|
| 1-yr | 3-yrs | 5-yrs | 1-yr | 3-yrs | 5-yrs | ||||
| Sex | |||||||||
| Male | 68 | 54.4% | 36.8% | 30.7% | 0.53 | 79.4% | 50.0% | 41.2% | 0.48 |
| Female | 16 | 56.3% | 37.5% | 37.5% | 87.5% | 56.3% | 50.0% | ||
| Age(yrs) | |||||||||
| <60 | 68 | 45.6% | 32.4% | 29.3% | 0.15 | 82.4% | 48.5% | 39.7% | 0.39 |
| ≥60 | 16 | 62.5% | 56.3% | 42.2% | 75.0% | 62.5% | 56.3% | ||
| HCC family history | |||||||||
| Yes | 6 | 50.0% | 33.3% | 16.7% | 0.57 | 83.3% | 50.0% | 50.0% | 0.63 |
| No | 78 | 48.7% | 37.2% | 33.3% | 79.5% | 51.3% | 42.3% | ||
| PLT(×109) | |||||||||
| <100 | 10 | 80.0% | 60.0% | 60.0% | 0.07 | 100.0% | 80.0% | 70.0% | 0.08 |
| ≥100 | 74 | 44.6% | 33.8% | 28.2% | 78.4% | 47.3% | 39.2% | ||
| HBsAg | |||||||||
| Positive | 72 | 47.2% | 38.9% | 33.3% | 0.90 | 79.2% | 50.0% | 44.4% | 0.88 |
| Negative | 12 | 58.3% | 25.0% | 25.0% | 91.7% | 58.3% | 33.3% | ||
| AFP(μg/L) | |||||||||
| <20 | 36 | 52.8% | 38.9% | 38.9% | 0.34 | 83.3% | 50.0% | 44.4% | 0.75 |
| ≥20 | 48 | 45.8% | 35.4% | 26.7% | 79.2% | 52.1% | 41.7% | ||
| Ascites | |||||||||
| No | 68 | 52.9% | 39.7% | 34.1% | 0.14 | 83.8% | 51.5% | 44.1% | 0.55 |
| Yes | 16 | 31.3% | 25.0% | 25.0% | 68.8% | 50.0% | 37.5% | ||
| Cirrhosis | |||||||||
| No | 24 | 45.0% | 35.0% | 30.0% | 0.78 | 95.0% | 60.0% | 45.0% | 0.49 |
| Yes | 60 | 50.0% | 37.5% | 32.9% | 76.6% | 48.4% | 42.2% | ||
| Tumor number | |||||||||
| Single | 62 | 59.7% | 43.5% | 36.9% | 0.003 | 85.5% | 61.3% | 51.6% | <0.001 |
| Multiple | 22 | 18.2% | 18.2% | 18.2% | 68.2% | 22.7% | 18.2% | ||
| PVTT | |||||||||
| No | 73 | 54.8% | 41.1% | 35.4% | <0.001 | 87.7% | 56.2% | 47.9% | <0.001 |
| Yes | 11 | 9.1% | 9.1% | 9.1% | 36.4% | 18.2% | 9.1% | ||
| Tumor size (cm) | |||||||||
| <5 | 34 | 64.7% | 47.1% | 39.2% | 0.05 | 97.1% | 67.6% | 52.9% | 0.04 |
| ≥5 | 50 | 38.0% | 30.0% | 28.0% | 70.0% | 40.0% | 36.0% | ||
| Tumor encapsulation | |||||||||
| None | 20 | 30.0% | 25.0% | 15.0% | 0.01 | 60.0% | 45.0% | 30.0% | 0.08 |
| Complete | 64 | 54.7% | 40.6% | 37.7% | 87.5% | 53.1% | 46.9% | ||
| Resection margin | |||||||||
| <2 cm | 45 | 40.0% | 26.7% | 24.4% | 0.07 | 80.0% | 40.0% | 28.9% | 0.01 |
| ≥2 cm | 39 | 59.0% | 48.7% | 39.6% | 82.1% | 64.1% | 59.0% | ||
| Complication | |||||||||
| No | 73 | 49.3% | 38.4% | 33.1% | 0.37 | 84.9% | 53.4% | 45.2% | 0.10 |
| Yes | 11 | 45.5% | 27.3% | 27.3% | 54.5% | 36.4% | 27.3% | ||
| Tumor differetiation | |||||||||
| I-II | 62 | 54.8% | 41.9% | 35.1% | 0.16 | 85.5% | 56.5% | 48.4% | 0.04 |
| III-IV | 22 | 31.8% | 22.7% | 22.7% | 68.2% | 36.4% | 27.3% | ||
| TNM stage | |||||||||
| I-II | 55 | 60.0% | 43.6% | 38.0% | 0.01 | 90.9% | 60% | 52.7% | 0.001 |
| III-IV | 29 | 27.6% | 24.1% | 20.7% | 62.1% | 34.5% | 24.1% | ||
| ELF expression | |||||||||
| Low | 44 | 25.0% | 15.9% | 10.2% | <0.001 | 72.7% | 31.8% | 23.7% | <0.001 |
| High | 40 | 75.0% | 60.0% | 57.5% | 90.0% | 72.5% | 65.0% | ||
| TGFβ1 expression | |||||||||
| Low | 34 | 79.4% | 73.5% | 62.0% | <0.001 | 94.1% | 85.3% | 76.5% | <0.001 |
| High | 50 | 28.0% | 12.0% | 12.0% | 72.0% | 28.0% | 20.0% | ||
